We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Organon (OGN) Soars 30.9%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Organon (OGN - Free Report) shares rallied 30.9% in the last trading session to close at $11.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 42.2% gain over the past four weeks.
Organon recorded a strong price rise on investors’ optimism following the announcement of its proposed acquisition by Sun Pharmaceutical Industries Limited (“Sun Pharma”). Under the agreement Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
This pharmaceutical company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of -17.7%. Revenues are expected to be $1.47 billion, down 3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Organon, the consensus EPS estimate for the quarter has been revised 2.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OGN going forward to see if this recent jump can turn into more strength down the road.
Organon is part of the Zacks Medical Services industry. InnovAge Holding Corp. (INNV - Free Report) , another stock in the same industry, closed the last trading session 2.7% higher at $7.95. INNV has returned -2.3% in the past month.
For InnovAge, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.06. This represents a change of +175% from what the company reported a year ago. InnovAge currently has a Zacks Rank of #1 (Strong Buy).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Organon (OGN) Soars 30.9%: Is Further Upside Left in the Stock?
Organon (OGN - Free Report) shares rallied 30.9% in the last trading session to close at $11.26. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 42.2% gain over the past four weeks.
Organon recorded a strong price rise on investors’ optimism following the announcement of its proposed acquisition by Sun Pharmaceutical Industries Limited (“Sun Pharma”). Under the agreement Sun Pharma will acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
This pharmaceutical company is expected to post quarterly earnings of $0.84 per share in its upcoming report, which represents a year-over-year change of -17.7%. Revenues are expected to be $1.47 billion, down 3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Organon, the consensus EPS estimate for the quarter has been revised 2.4% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on OGN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Organon is part of the Zacks Medical Services industry. InnovAge Holding Corp. (INNV - Free Report) , another stock in the same industry, closed the last trading session 2.7% higher at $7.95. INNV has returned -2.3% in the past month.
For InnovAge, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.06. This represents a change of +175% from what the company reported a year ago. InnovAge currently has a Zacks Rank of #1 (Strong Buy).